Summary & Overview
HCPCS A9603: Injection of Pafolacianine, 0.1 mg
HCPCS Level II code A9603 denotes an injection of pafolacianine, 0.1 mg, an injectable imaging agent used to aid visualization of lesions during diagnostic or intraoperative imaging. Nationally, this code matters because it captures utilization and billing for a specialized contrast agent that supports targeted imaging, surgical planning, and intraoperative guidance across outpatient and hospital settings.
Key payers included in this coverage analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of payer coverage patterns, common billing considerations, and the clinical context in which pafolacianine is used. The publication summarizes available benchmarks for utilization and reimbursement where provided by payers, highlights recent policy developments affecting imaging agent billing, and explains operational implications for sites of service that administer injectable imaging agents.
The report is intended for healthcare administrators, coding and billing professionals, and clinical leaders seeking a national-level briefing on coding, payment, and clinical application of pafolacianine injection captured by HCPCS Level II code A9603.
Billing Code Overview
HCPCS Level II code A9603 represents an injection of pafolacianine, 0.1 mg. This medication is used as an injectable imaging agent to assist clinicians in identifying certain lesions during procedures that require tumor visualization.
-
Service type: Diagnostic imaging agent administration
-
Typical site of service: Outpatient imaging suite, ambulatory surgery center, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old woman with a history of suspected or known non-small cell lung carcinoma (NSCLC) is scheduled for intraoperative fluorescence-guided surgery. The patient receives an intravenous injection of pafolacianine prior to surgical exposure to assist the surgical team in localizing tumor tissue with near-infrared imaging. Typical workflow: preoperative consent and assessment in the ambulatory surgical center or hospital pre-op unit; pharmacy prepares A9603 (pafolacianine) in the appropriate concentration and dose increments per 0.1 mg billing unit; nursing administers the drug intravenously over the recommended interval before imaging; the operating room team uses an NIR imaging system during resection to identify fluorescent lesions; post-procedure observation in PACU followed by routine postoperative documentation of drug administration, imaging findings, and any adverse events.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier/standard reporting | Use when no special circumstances apply to the service. |
22 | Increased procedural services |